Premium
Drug Targeting: Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug‐Loaded Magnetic Solid Lipid Nanoparticles (Adv. Healthcare Mater. 11/2015)
Author(s) -
Grillone Agostina,
Riva Eugenio Redolfi,
Mondini Alessio,
Forte Claudia,
Calucci Lucia,
Innocenti Claudia,
de Julian Fernandez Cesar,
Cappello Valentina,
Gemmi Mauro,
Moscato Stefania,
Ronca Francesca,
Sacco Rodolfo,
Mattoli Virgilio,
Ciofani Gianni
Publication year - 2015
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201570068
Subject(s) - sorafenib , drug , nanoparticle , in vitro , materials science , magnetic nanoparticles , nanotechnology , solid lipid nanoparticle , pharmacology , chemistry , cancer research , medicine , biochemistry , hepatocellular carcinoma
Sorafenib‐loaded magnetic solid lipid nanoparticles are highly internalized by HepG2 human hepatocarcinoma cells. As described by A. Grillone, G. Ciofani, and co‐workers on page 1681, the uptake of the nanoparticles can be directed by modulating their accumulation through an external magnetic field, thus focusing the drug effects at a desired site.